United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
316 USD +2.28% Intraday chart for United Therapeutics Corporation +9.71% +43.73%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing MT
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024. CI
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing MT
Chart United Therapeutics Corporation
More charts
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
316 USD
Average target price
295.9 USD
Spread / Average Target
-6.36%
Consensus
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. News United Therapeutics Corporation
  5. United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing